OBJECTIVE:Nevirapine and cotrimoxazole are associated with hematologic toxicities and skin-rash. Safety of their concurrent use for prophylaxis over extended periods among HIV-exposed uninfected infants has not been previously assessed. DESIGN: Secondary data analysis of the 'HIV Prevention Trials Network-046 protocol' (version 2.0), a phase-III, randomized, placebo-controlled trial that assessed efficacy and safety of nevirapine prophylaxis against breast milk transmission of HIV-1. METHODS: Trial infants received 6-month study nevirapine/placebo, and standard-of-care peripartum single-dose nevirapine+/- zidovudine 'tail', and cotrimoxazole prophylaxis from 6 weeks through breastfeeding cessation. Adverse events were monitored using United States Division of AIDS Toxicity Tables (2004). Risk of neutropenia, anemia and skin-rash in the cotrimoxazole + nevirapine and the cotrimoxazole + placebo groups were compared using negative-binomial regression. RESULTS:Incidence of neutropenia and/or anemia, and skin-rash was highest during the first 6 weeks of life and declined, thereafter, regardless of study group. Time to first adverse event after 6 weeks was similar in cotrimoxazole + nevirapine and cotrimoxazole + placebo groups: hazard ratio (95% confidence interval) was 1.26 (0.96-1.66) for neutropenia and/or anemia (all grades), 1.27 (0.80-2.03) for neutropenia and/or anemia (grade ≥3) and 1.16 (0.46-2.90) for skin-rash (grade ≥2). There were no statistically significant differences in immediate (6 weeks-6 months) and long-term (6-12 months) adverse event risk among infants on cotrimoxazole + nevirapine versus cotrimoxazole + placebo. CONCLUSION: Extended nevirapine and cotrimoxazole prophylaxis through 6 months of age among HIV-exposed uninfected infants did not appear to increase the immediate or long-term risk of neutropenia, anemia or skin-rash. Concurrent use beyond 6 months, however, needs to be evaluated.
RCT Entities:
OBJECTIVE:Nevirapine and cotrimoxazole are associated with hematologic toxicities and skin-rash. Safety of their concurrent use for prophylaxis over extended periods among HIV-exposed uninfected infants has not been previously assessed. DESIGN: Secondary data analysis of the 'HIV Prevention Trials Network-046 protocol' (version 2.0), a phase-III, randomized, placebo-controlled trial that assessed efficacy and safety of nevirapine prophylaxis against breast milk transmission of HIV-1. METHODS: Trial infants received 6-month study nevirapine/placebo, and standard-of-care peripartum single-dose nevirapine+/- zidovudine 'tail', and cotrimoxazole prophylaxis from 6 weeks through breastfeeding cessation. Adverse events were monitored using United States Division of AIDS Toxicity Tables (2004). Risk of neutropenia, anemia and skin-rash in the cotrimoxazole + nevirapine and the cotrimoxazole + placebo groups were compared using negative-binomial regression. RESULTS: Incidence of neutropenia and/or anemia, and skin-rash was highest during the first 6 weeks of life and declined, thereafter, regardless of study group. Time to first adverse event after 6 weeks was similar in cotrimoxazole + nevirapine and cotrimoxazole + placebo groups: hazard ratio (95% confidence interval) was 1.26 (0.96-1.66) for neutropenia and/or anemia (all grades), 1.27 (0.80-2.03) for neutropenia and/or anemia (grade ≥3) and 1.16 (0.46-2.90) for skin-rash (grade ≥2). There were no statistically significant differences in immediate (6 weeks-6 months) and long-term (6-12 months) adverse event risk among infants on cotrimoxazole + nevirapine versus cotrimoxazole + placebo. CONCLUSION: Extended nevirapine and cotrimoxazole prophylaxis through 6 months of age among HIV-exposed uninfected infants did not appear to increase the immediate or long-term risk of neutropenia, anemia or skin-rash. Concurrent use beyond 6 months, however, needs to be evaluated.
Authors: Jonathan Mermin; John Lule; John Paul Ekwaru; Samuel Malamba; Robert Downing; Ray Ransom; Frank Kaharuza; David Culver; Francis Kizito; Rebecca Bunnell; Aminah Kigozi; Damalie Nakanjako; Winnie Wafula; Robert Quick Journal: Lancet Date: 2004 Oct 16-22 Impact factor: 79.321
Authors: Avinash K Shetty; Hoosen M Coovadia; Mark M Mirochnick; Yvonne Maldonado; Lynne M Mofenson; Susan H Eshleman; Thomas Fleming; Lynda Emel; Kathy George; David A Katzenstein; Jennifer Wells; Charles C Maponga; Anthony Mwatha; Samuel Adeniyi Jones; Salim S Abdool Karim; Mary T Bassett Journal: J Acquir Immune Defic Syndr Date: 2003-12-15 Impact factor: 3.731
Authors: Gwenda Verweel; Mike Sharland; Hermione Lyall; Vas Novelli; Diane M Gibb; Gillian Dumont; Colin Ball; Ed Wilkins; Sam Walters; Gareth Tudor-Williams Journal: AIDS Date: 2003-07-25 Impact factor: 4.177
Authors: Elizabeth M Widen; Margaret E Bentley; Charles S Chasela; Dumbani Kayira; Valerie L Flax; Athena P Kourtis; Sascha R Ellington; Zebrone Kacheche; Gerald Tegha; Denise J Jamieson; Charles M van der Horst; Lindsay H Allen; Setareh Shahab-Ferdows; Linda S Adair Journal: J Acquir Immune Defic Syndr Date: 2015-07-01 Impact factor: 3.731
Authors: Anna Dow; Dumbani Kayira; Michael Hudgens; Annelies Van Rie; Caroline C King; Sascha Ellington; Athena Kourtis; Abigail Norris Turner; Steven Meshnick; Zebrone Kacheche; Denise J Jamieson; Charles Chasela; Charles van der Horst Journal: Pediatr Infect Dis J Date: 2012-08 Impact factor: 2.129
Authors: Alexander C Ewing; Caroline C King; Jeffrey B Wiener; Charles S Chasela; Michael G Hudgens; Debbie Kamwendo; Gerald Tegha; Mina C Hosseinipour; Denise J Jamieson; Charles Van der Horst; Athena P Kourtis Journal: AIDS Date: 2017-11-28 Impact factor: 4.177
Authors: Irene Njuguna; Marie Reilly; Walter Jaoko; Christine Gichuhi; Gwen Ambler; Elizabeth Maleche-Obimbo; Barbara Lohman-Payne; Tomáš Hanke; Grace John-Stewart Journal: Retrovirology (Auckl) Date: 2014-02-13
Authors: Scott Dryden-Peterson; Oluwemimo Jayeoba; Michael D Hughes; Haruna Jibril; Kenneth McIntosh; Taolo A Modise; Aida Asmelash; Kathleen M Powis; Max Essex; Roger L Shapiro; Shahin Lockman Journal: PLoS One Date: 2013-09-23 Impact factor: 3.240